Search Results - patricia+dranchak

3 Results Sort By:
Development of a Therapy for the Treatment of Zellweger Spectrum Disorder
This technology includes a method for selecting a therapeutic effective amount of one of two compounds (including naltriben and naltrin) for the treatment of Zellweger Spectrum Disorder (ZSD), or any disease associated with peroxisome dysfunction. The compounds were identified using a cell-image based high-content screening (HCS) assay to identify small...
Published: 10/28/2024   |   Inventor(s): Patricia Dranchak, James Inglese
Keywords(s): DEVELOP, DISORDER, Spectrum, THERAPY, TOOLS, treatment, VEXXXX, WIXXXX, WKXXXX, Zellweger
Category(s): TherapeuticArea > Neurology, Application > Therapeutics, Application > Research Materials
Potential New Drugs for Treating or Preventing Pruritus
NIH scientists have identified new compositions that could potentially be used to treat or prevent pruritus (itchiness). The newly discovered compounds can block a newly identified itch pathway and might be effective for persistent itch caused by psoriasis, atopic dermatitis, renal failure, liver cirrhosis and chemotherapy. These compounds are different...
Published: 10/28/2024   |   Inventor(s): Hans Solinski, James Inglese, Patricia Dranchak, Mark Hoon
Keywords(s): BLOCKAGE, IB6XXX, Itch, Listed LPM Vepa as of 4/15/2015, Nppb, Npr1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, Sensation, TRANSMITTER, treatment, VOXXXX, VPXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX
Category(s): TherapeuticArea > Reproductive Health, TherapeuticArea > Oncology, Application > Consumer Products, TherapeuticArea > Infectious Disease, ResearchProducts > Research Equipment, TherapeuticArea > Ophthalmology, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, TherapeuticArea > Cardiology
Potent and Selective Cyclic Peptide Inhibitors of Phosphoglycerate Mutase as Anti-Infective Agents
Summary – The invention includes compounds and compositions for inhibiting phosphoglycerate mutase (PGM) activity. In some examples, the compounds selectively inhibit cofactor-independent PGM (iPGM). In particular embodiments, the compounds include one or more cyclic peptides. Brief Background – Co-factor independent phosphoglycerate mutase (iPGM)...
Published: 10/28/2024   |   Inventor(s): Patricia Dranchak, Ryan Macarthur, James Inglese
Keywords(s): Agents, Anti-infective, Cyclic, DB2XXX, DB3XXX, Inhibitors, Mutase, Peptide, Phosphoglycerate, POTENT, SELECTIVE, VJXXXX, VQXXXX
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics